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Cleavage of the amyloid precursor protein (APP) by α-secretase generates an
extracellularly released fragment termed secreted APP-alpha (APPsα). Not only is this
process of interest due to the cleavage of APP within the amyloid-beta sequence, but
APPsα itself has many physiological properties that suggest its great potential as a
therapeutic target. For example, APPsα is neurotrophic, neuroprotective, neurogenic,
a stimulator of protein synthesis and gene expression, and enhances long-term
potentiation (LTP) and memory. While most early studies have been conducted in vitro,
effectiveness in animal models is now being confirmed. These studies have revealed that
either upregulating α-secretase activity, acutely administering APPsα or chronic delivery
of APPsα via a gene therapy approach can effectively treat mouse models of Alzheimer’s
disease (AD) and other disorders such as traumatic head injury. Together these findings
suggest the need for intensifying research efforts to harness the therapeutic potential of
this multifunctional protein.
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INTRODUCTION
Secreted amyloid precursor protein-alpha (APPsα, also known as soluble APPα), when generated
from the neuronally expressed APP695 isoform by the action of α-secretase (Figure 1), is a
612 amino acid protein that was first shown in the mid-1990s to promote the survival and growth
of cultured neurons under physiological and non-physiological conditions (e.g., glucose and
oxygen deprivation, amyloid-β (Aβ) toxicity; Mattson et al., 1993; Barger and Mattson, 1996a;
Furukawa et al., 1996). These observations have been supported and extended by myriad reports
over the intervening years (Ryan et al., 2013; Hefter et al., 2016) and has generated suggestions that
the promotion of α-secretase cleavage of APP and increasing APPsα levels could be a therapeutic
strategy for the treatment of Alzheimer’s disease (AD; Turner et al., 2003; Ring et al., 2007;
Postina, 2012; Hick et al., 2015; Fol et al., 2016; Habib et al., 2016) and possibly other neurological
disorders. The purpose of this review is to consider the extent to which APPsα generation may be
disrupted in AD, and summarize the many positive functions of APPsα that could be lost in the
disease. In addition we will discuss the potential that either enhancement of non-amyloidogenic
processing of APP or upregulating the expression of APPsα by other means has for preventing
or at least slowing the progression of AD as well as treating other neurological disorders.
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APP PROCESSING
APP is a single pass type I transmembrane protein that undergoes
complex proteolytical processing by several enzymes termed
secretases. In the amyloidogenic pathway, APP processing is
initiated by β-secretase (β-amyloid cleaving enzyme, BACE-1),
a transmembrane aspartate-type protease (for review see Vassar
et al., 2014) that cleaves APP at the N-terminus of Aβ,
leading to the secretion of the soluble ectodomain APPsβ
(Figure 1A). In the competing and physiologically predominant
non-amyloidogenic pathway, α-secretase cleaves APP within the
Aβ region (Figure 1A), in a process that can be stimulated
by neuronal and synaptic activity (Hoey et al., 2009; Hoe
et al., 2012). This not only prevents the formation of Aβ
peptides but also leads to the secretion of the ectodomain
APPsα, which is only 16 amino acids longer than APPsβ
(Figure 1B), into the extracellular space. Several members
of the ADAM (a disintegrin and metalloprotease) family
including ADAM9, ADAM10 and ADAM17, transmembrane
Zn-proteases located at the cell surface, are able to cleave
APP at the α-secretase site in vitro (reviewed by Saftig and
Lichtenthaler, 2015). In neurons ADAM10 serves as the major
physiological α-secretase as demonstrated by pharmacological
inhibition and knockdown in vitro, as well as brain-specific
knockout (KO) in vivo (Kuhn et al., 2010; Colombo et al.,
2013; Prox et al., 2013). Subsequent processing of the membrane
tethered C-terminal fragment resulting from β-secretase activity
(CTFβ) by γ-secretase liberates Aβ and the APP intracellular
domain (AICD), while CTFα processing yields the p3 fragment.
γ-secretase cleavage occurs within themembrane by a complex of
transmembrane proteins containing as a catalytic core presenilin
(PS) 1 or 2. In wild-type neurons the predominant Aβ species
generated is Aβ40, whereas familial forms of AD (FAD) linked
to PS1 mutations result in a higher proportion of longer, more
aggregation prone Aβ species including Aβ42 and Aβ43 that
are believed to trigger plaque deposition (Veugelen et al.,
2016).
ALZHEIMER’S DISEASE
AD is a progressive neurodegenerative disease for which
aging is the most significant risk factor. It has traditionally
been diagnosed by the appearance of functional deficits that
frequently begin with self-reporting of impaired episodic
memory (Dubois et al., 2007). Definitive diagnosis, however,
requires post-mortem confirmation, although in recent
times a number of biomarkers are providing new ways of
diagnosing in life, such as medial temporal lobe atrophy
with hippocampi volume loss, abnormal cerebrospinal
fluid levels of the neurotoxic Aβ peptide and tau protein,
plus positron emission tomography evidence for amyloid
plaques and reduced glucose metabolism (Jack and Holtzman,
2013). While the proximal causes of sporadic AD are largely
unknown, the familial forms arise when any one of several
autosomal dominant mutations in genes regulating the
production and clearance of Aβ are present (Dubois et al.,
2007, 2010).
The post-mortem neuropathology of AD is characterized by
the extensive development of extracellular plaques containing
Aβ that are generated by amyloidogenic processing of APP
(Figure 1A), intraneuronal hyperphosphorylated tau leading
to neurofibrillary tangles, neuroinflammation and cell loss.
Moreover, accumulation of intraneuronal Aβ has been observed
as an early event in transgenic animal models (Kumar et al.,
2013) and may contribute to pathogenesis (Zou et al., 2015; Ji
et al., 2016). Sub-clinical progression of AD may occur over
15–20 years prior to diagnosis (Jack and Holtzman, 2013). This
early phase of the disease is characterized by the formation of
soluble oligomeric forms of Aβ that cause neuronal dysfunction
and toxicity that may underpin early cognitive deficits. At the
center of this early dysfunction in particular is impairment of
synaptic function. Investigations in both AD patients and in
mouse models of AD have revealed significant reductions in
dendritic spine density in both cortical and subcortical regions
early in the disease that are highly correlated with the appearance
of cognitive deficits (Scheff et al., 1990, 2006; Terry et al., 1991;
Spires-Jones and Knafo, 2012). Compensatory enlargement of
remaining synapses has been reported and may mitigate some
of the early losses in spine density; as AD progresses, however,
spine loss exceeds synaptic growth leading to a net reduction in
synaptic transmission (Scheff et al., 1990). Further progression
of AD results in loss of dendritic complexity (reduced length,
less branching, changes in dendrite diameter) and eventually cell
death (Alpár et al., 2006).
An important pathology associated with synaptic dysfunction
is the impairment in the synaptic plasticity mechanisms
hypothesized to underpin learning and memory. The most
extensively studied form of synaptic plasticity, long-term
potentiation (LTP), is reliably impaired in most animal models
of AD and can also be caused by extracts obtained from
post-mortem AD brain (Oddo et al., 2003; Shankar et al., 2008;
Li et al., 2011). The impairment of LTP observed in animal
models and from raised Aβ levels may in part relate to altered
transmission and loss of dendritic spines (reviewed by Spires-
Jones and Knafo, 2012), as well as impairments in N-methyl-
D-aspartate (NMDA) receptor expression and inhibition of
LTP-associated de novo protein synthesis (Snyder et al., 2005; Li
et al., 2011).
The treatment of AD has proven to be extremely challenging.
Despite an exhaustive array of clinical trials that now number
in the hundreds (Schneider et al., 2014), no disease-modifying
treatments have proven effective for clinical use, although there
is renewed hope arising from a recent study that has given
very promising results from anti-Aβ antibody treatment (Sevigny
et al., 2016). On the other hand, a lack of significant cognitive
improvements was recently reported for a phase III clinical trial
in patients with mild AD (EXPEDITION-3) using Solanezumab,
an anti-Aβ antibody that binds only soluble Aβ (Hawkes, 20161).
Thus, at present only two classes of drugs have been approved
by the Food and Drug Administration for AD treatment and
these only address the symptoms of the disease (Geldenhuys and
Darvesh, 2015). Acetylcholinesterase inhibitors (e.g., donepezil)
1http://www.ctad-alzheimer.com/live-webcast
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FIGURE 1 | Proteolytic processing of murine amyloid precursor protein (APP). (A) Schematic overview of murine APP processing via the amyloidogenic (red
dotted box) and the non-amyloidogenic (green dotted box) pathways. Processing by α-secretase within the amyloid-β (Aβ) region prevents Aβ generation and leads
to the secretion of secreted APPα (APPsα) and harmless p3. In contrast, processing along the amyloidogenic pathway by β- and γ-secretase cleavage leads to Aβ
production and liberates APPsβ. An intracellular fragment (AICD) involved in transcriptional regulation is released in both pathways. The position of cleavage sites is
indicated by arrowheads. (B) Comparison of the C-termini of APPsα and APPsβ that differ only in the last 16 residues (highlighted as a red box).
target the reduced cholinergic innervation of the hippocampus
and cortex resulting from the loss of basal forebrain cholinergic
neurons (Whitehouse et al., 1982), and memantine targets the
increased tonic activation of extrasynaptic NMDA receptors that
leads to activation of apoptotic pathways and neuronal death
(Hardingham and Bading, 2010). While these treatments provide
some symptomatic relief, their efficacy invariably reduces over
time and ultimately they fail to halt or reverse the progression
of the disease. Therefore, it is vital that new treatment options
continue to be explored.
A SHIFT IN THE BALANCE OF
α-SECRETASE VERSUS β-SECRETASE
ACTIVITY?
The amyloid cascade hypothesis has been the most widely
supported explanation of the pathology that drives the
progression of AD (De Strooper and Karran, 2016; Selkoe and
Hardy, 2016), although other elements of the neuropathology
are gaining increasing attention (Herrup, 2015; Rius-Pérez et al.,
2015; Briggs et al., 2016). The amyloid cascade hypothesis
contends that there is either a shift in APP processing towards the
amyloidogenic pathway, or there is a reduction in Aβ clearance
which results in the excessive accumulation of Aβ and a shift in
the ratio of the various Aβ species to favor Aβ42. There is also
evidence that BACE1 is upregulated during aging and AD, thus
favoring amyloidogenic APP processing (Fukumoto et al., 2002,
2004; Holsinger et al., 2002; Yang et al., 2003; Li et al., 2004;
Ahmed et al., 2010).
With the firm focus on increased levels of both soluble and
insoluble Aβ in the brain and cerebrospinal fluid (CSF) in AD,
relatively little attention has been given to a possible associated
reduction in α-secretase activity and thus a shift away from
the production of APPsα that might amplify the toxic effects
of Aβ, hyperphosphorylated tau and other neuropathologies.
However, the evidence for a reduction in APPsα levels in AD
is mixed. Measuring mixed alpha and beta forms of secreted
APP, Kibbey et al. (1993) reported that levels of APPs in the
CSF of AD patients were 3.5 times lower than that in healthy
controls. Subsequent studies specifically measuring APPsα in
CSF supported this finding (Lannfelt et al., 1995; Almkvist et al.,
1997; Sennvik et al., 2000), and positive correlations between
reduced APPsα levels and diminished performance in cognitive
testing in both AD patients (Almkvist et al., 1997) and normal
aged rats (Anderson et al., 1999) have been reported. The loss
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of cholinergic innervation from the basal forebrain to the cortex
and hippocampus in the very earliest stages of AD may underlie
the loss of APPsα production and this may be the driver for
the shift to amyloidogenic processing of APP (Obregon et al.,
2012).
On the other hand, there is also evidence that APPsα
levels may not be changed in the early stages of sporadic AD
(Perneczky et al., 2014). Several studies using newly developed
methodologies have reported that APPsα CSF and blood plasma
levels are unchanged in sporadic AD patients (Olsson et al., 2003;
Perneczky et al., 2011, 2013; Rosén et al., 2012; Brinkmalm et al.,
2013) with decreases only in advanced AD (Rosén et al., 2012)
and in AD patients carrying the ApoE-ε4 allele (Olsson et al.,
2003). One study has even reported an increase in APPsα levels
in the CSF of AD patients (Rosén et al., 2012). Thus, a complete
understanding of the pattern of APPsα production in AD and its
significance will require more detailed study of AD patients and
testing in animal models of the disease.
While the production of APPsα in the brain still needs
to be fully understood, evidence from studies in humans and
animals indicates that reduced APPsα levels can exacerbate
AD symptoms. A mutation at the α-secretase cleavage site
of human APP (APP770K687N) was found to cause early
onset dementia. The mutation severely reduced α-cleavage
and thus APPsα production, but at the same time led to
the production of highly toxic Aβ species, hampering a clear
interpretation of the specific impact of low APPsα levels (Kaden
et al., 2012). However, Epis et al. (2010) demonstrated that
hippocampal ADAM10/SAP97 levels (a complex required for
synaptic ADAM10 localization) are reduced in AD patients,
while activity-attenuating mutations in the prodomain of the
human ADAM10 gene have been associated with AD (Kim et al.,
2009; Suh et al., 2013). Reducing ADAM10 activity in adult
mice by impairing its trafficking (Epis et al., 2010) or through
forebrain-specific conditional ADAM10 KO (Prox et al., 2013)
shifted APP processing towards Aβ production. Together these
data suggest that reduced APPsα levels may contribute to the
early stages of sporadic AD.
PROPERTIES AND FUNCTIONS OF APPsα
The possible significance of any impairments in
ADAM10 activity or in the expression of APPsα becomes
quickly apparent when one considers that this protein exerts
a large number of growth factor-like properties when applied
exogenously to neural tissue. Understanding the functionality of
this protein, and its mechanisms of action, is crucial not only for
understanding its biology in normal tissue, but also for providing
critical information that will underpin any attempt to harness its
potential therapeutic benefits (Figure 2).
NEUROPROTECTION
APPsα has strong neuroprotective properties that mitigate in
cultured neurons the effects of a range of pro-apoptotic insults
including hypoglycemia and glutamate toxicity (Mattson et al.,
1993; Furukawa et al., 1996) and, importantly, Aβ-induced
FIGURE 2 | Shifting the balance between APPsα and Aβ to ameliorate
Alzheimer’s disease (AD). Top left (gray): under physiological conditions,
balanced levels of APPsα and Aβ are generated as products of normal brain
metabolism. Top right (red): during AD, Aβ accumulates due to increased Aβ
production and/or reduced Aβ clearance. Aβ accumulation in oligomers and
plaques inhibits synaptic function, synaptic plasticity and cognition and
ultimately leads to neuronal death. Middle (green): beneficial properties of
APPsα that may be exploited to counteract the Aβ load and to ameliorate the
symptoms and possibly the pathogenesis of AD. Bottom: strategies to shift
the balance of APP processing towards the non-amyloidogenic pathway.
toxicity (Goodman and Mattson, 1994; Barger and Mattson,
1996a,b; Furukawa et al., 1996; Guo et al., 1998). More recently,
we and others have demonstrated that the effects of other
disease-associated insults such as excessive NMDA receptor
activation (Ryan et al., 2013) and proteasomal impairments
(Copanaki et al., 2010; Kundu et al., 2016) can be mitigated by
APPsα administration. APPsα inhibits the upregulation of the
co-chaperone BAG3 and suppresses BAG3-mediated aggresome
formation under conditions of proteasomal stress (Kundu et al.,
2016). Moreover, APPsα is a key activator of the PI3K/Akt
survival signaling pathway that is triggered in response to serum
withdrawal in cultured neurons (Milosch et al., 2014). Although
the mechanisms conferring neuroprotection are only partially
understood (for review see Kögel et al., 2012), some of these
effects depend on the binding of APPsα to cell surface APP,
that via its C-terminal domain can interact with G0 protein
to trigger the pro-survival Akt kinase pathway (Milosch et al.,
2014).
While most previous studies focused on cell death, the
impact of APP on cellular and neuronal network functions
during metabolic stress remain largely unknown. In this
regard, Hefter et al. (2016) recently studied hypoxia-induced
loss of function and recovery upon re-oxygenation in mouse
hippocampal slices. While APP-KO mice showed impaired
functional recovery after transient hypoxia, this could be largely
rescued by APPsα expression or by pharmacological block of
L-type calcium channels. Voltage-gated Ca2+ channels are, in
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addition to NMDARs and internal Ca2+ stores, major sources of
intracellular calcium contributing to traumatic/ischemic insults
and AD pathogenesis. These data indicated that APP, in
particular APPsα, supports neuronal resistance against acute
hypoxia by regulating calcium homeostasis (Hefter et al.,
2016).
In addition to these in vitro studies, there is also evidence
that APPsα may protect against acute forms of brain injury
in vivo. Smith-Swintosky et al. (1994) demonstrated that
APPsα ameliorates neuron loss in the hippocampus under
conditions of transient ischemia, consistent with subsequent
findings that APP-KO mice show increased acute mortality
upon ischemia (Koike et al., 2012). In addition, a series
of recent experiments have shown a protective effect of
APPsα in traumatic brain injury (reviewed by Plummer et al.,
2016). Intracerebroventricular (ICV) administration of APPsα
following traumatic injury in rats significantly reduced cell and
axonal death and improved motor outcomes (Corrigan et al.,
2014). While APP-KO mice are more vulnerable to traumatic
brain injury this could be rescued by recombinant APPsα
or peptides derived from it (Corrigan et al., 2014; Plummer
et al., 2016). Together these data indicate that endogenous
APPsα is neuroprotective under injury conditions and suggest
that these properties may be exploited in a therapeutic
setting.
In a positive feedback cycle, APPsα may promote the
further production of APPsα by blocking the amyloidogenic
pathway through binding to and inhibiting the β-secretase
BACE1 (Peters-Libeu et al., 2015), leading to a reduction in
Aβ production (Obregon et al., 2012; but see also Fol et al.,
2016). Further protection against AD-related toxicity by APPsα
may arise from the inhibition of the tau phosphorylating
enzyme GSK3β, thus reducing tau hyperphosphorylation and the
subsequent production of NFTs (Deng et al., 2015).
TROPHIC FUNCTIONS: CELL
PROLIFERATION AND ADULT
NEUROGENESIS
In addition to neuroprotection, APPsα exerts trophic functions
both in vitro and in vivo. Early studies indicated that
APPsα restores the growth of fibroblasts in which endogenous
APP expression had been attenuated (Saitoh et al., 1989),
stimulates thyroid epithelial cell growth (Pietrzik et al., 1998)
and enhances the proliferation of rat fetal neural stem cells
(Hayashi et al., 1994; Ohsawa et al., 1999). While these trophic
functions appear beneficial under physiological conditions,
enhanced APPsα expression has been detected in different
tumors including glioblastoma (for review see Chasseigneaux
and Allinquant, 2012). APPsα has also been implicated in
adult neurogenesis. APP knockdown in adult mice resulted
in reduced numbers of neurospheres that could be cultured
form the ventricular zone (Caillé et al., 2004) and an
APP-Fc fusion protein (Fc domain of IgG fused to the APP
ectodomain) was shown to bind to the subventricular zone
of adult mice (Caillé et al., 2004), suggesting that APPsα
may stimulate neuronal stem/progenitor cell proliferation.
Consistent with these findings, APPsα infusion into the lateral
ventricle increased the number of EGF-responsive progenitor
cells (Caillé et al., 2004), while pharmacological blockade of
α-secretase by infusion of the inhibitor batimastat decreased
the number of neuronal progenitors in vivo (Caillé et al.,
2004). This was further corroborated by in vitro studies
indicating that APPsα stimulates the proliferation of cultured
neuronal precursor cells (NPCs) from the adult subventricular
zone even in the absence of EGF (Demars et al., 2011) and
also NPCs from the dentate gyrus (Baratchi et al., 2012).
Consistent with the latter finding, transgenic overexpression
of ADAM10 led to increased hippocampal neurogenesis (Suh
et al., 2013). In addition, intraventricular injection of APPsα
rescued the age-dependent decline in the number of NPCs in vivo
(Demars et al., 2013). Taken together these findings indicate
a prominent role of APPsα in adult neuronal progenitor cell
proliferation.
ROLE FOR NEURITE OUTGROWTH,
SYNAPTOGENESIS AND SPINE DENSITY
Several in vitro studies indicated that APPsα can promote
neurite (Clarris et al., 1994; Small et al., 1994) and axonal
outgrowth (Young-Pearse et al., 2008). Several APP domains
important for these functions have been identified including the
N-terminal APP96–110 region located in the first heparin-binding
domain and the APP319–335 region which contains the RERMS
motif (Ninomiya et al., 1994). Studies from animal models
also indicate a crucial role for APPsα in synaptogenesis and
modulation of spine density. Using organotypic hippocampal
cultures we have demonstrated a pronounced decrease in
spine density and reductions in the number of mushroom
spines thought to represent mature synapses in CA1 pyramidal
neurons of APP-KO mice. Interestingly, APPsα expression
alone was sufficient to prevent the defects in spine density
observed in APP-KO mice, as APPsα knock-in mice that lack
transmembrane APP and express solely the secreted APPsα
fragment exhibited unaltered spine density and spine type
distribution (Weyer et al., 2014). In line with this, APPsα
could also partially restore spine density deficits of cultured
APP-KO neurons (Tyan et al., 2012). In turn, these findings
imply that autocrine or paracrine APPsα signaling, important
for spine formation and/or maintenance, involves a so far
unknown receptor distinct from APP itself. Further support
for a synaptotrophic role of APPsα comes from transgenic
mice with moderate overexpression of human wild-type APP
(Mucke et al., 1996) or indirect up-regulation of APPsα
by transgenic expression of the α-secretase ADAM10 (Bell
et al., 2008), which both led to increased synaptic density.
In Tg2576 mice, expression of mutant hAPP increased spine
density in CA1 and cortical neurons of young mice prior
to plaque deposition presumably via APPsα, whereas spine
density was decreased in aged animals, likely due to Aβ-
mediated synaptotoxic effects (Lee et al., 2010). This suggests that
APPsα might counteract Aβ-mediated effects on spine density
during early stages of pathogenesis. Recent evidence indicates
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that APP also regulates spine plasticity. Using two-photon
in vivo microscopy, (Zou et al., 2016) analyzed cortical spine
dynamics in vivo and reported decreased spine turnover rates
(formation of new spines or loss of established spines) in
APP-KO mice. Moreover, when housed under environmental
enrichment, APP-KO mice failed to respond with an increase
in spine density (Zou et al., 2016), suggesting that not only
a reduction in spine numbers but also alterations in spine
dynamics could contribute to deficits in synaptic plasticity and
behavior found in APP mutant mice (Dawson et al., 1999;
Seabrook et al., 1999; Ring et al., 2007). It remains to be
seen which domains of APP or which proteolytic fragment is
important for this function. The mechanism underlying the
effects of APPsα on spines is presently unknown, although
NMDARs could play a crucial role. APP-KO mice have
decreased levels of extracellular D-serine (Zou et al., 2016), an
essential endogenous co-factor of NMDAR activation (Panatier
et al., 2006). Taken together these findings indicate important
synaptogenic and synaptic modifying properties of APPsα
that may be of therapeutic value (Fol et al., 2016; see also
below).
SYNAPTIC PLASTICITY
Synaptic plasticity phenomena, such as LTP and long-term
depression (LTD), are fundamental to learning and memory
and are thus also central to normal cognitive function. In
mouse models of AD, LTP is consistently impaired in an
age-dependent fashion (Oddo et al., 2003; Vigot et al., 2006),
and in some cases LTD is facilitated (Megill et al., 2015),
while humans with diagnosed AD also show impaired synaptic
plasticity (Trebbastoni et al., 2016). It is interesting to note
then that APPsα has the capacity to facilitate LTP and thus
has the potential to counter the LTP-impairing effects of Aβ.
In an early study, Ishida et al. (1997) demonstrated that
APPsα increased the frequency dependency of LTD induction
in CA1 from 1 Hz to 10 Hz and facilitated LTP expression
induced by 100 Hz stimulation, possibly by a protein kinase
G (PKG)-dependent mechanism. Moreover, we showed in
anesthetized rats that exogenously applied APPsα exerted an
inverted U-shaped dose-dependent facilitation of LTP in the
dentate gyrus, although too high a dose impaired LTP (Taylor
et al., 2008). Moreover, APPsα antibodies as well as an
α-secretase inhibitor impaired LTP, and the latter effect could
be rescued by exogenous APPsα but not by APPsβ, despite
its lacking only the 16 C-terminal residues when compared
to APPsα (Figure 1B). The inhibition of LTP appeared to be
mediated, at least in part, through a reduction of NMDAR
currents generated during the high-frequency stimulation (HFS).
No effects on basal AMPA or NMDA receptor currents
were observed, suggesting that endogenous APPsα may be
released during the HFS to contribute to LTP. However
this point requires further study, as the effect of α-secretase
inhibition on tetanic NMDA receptor currents was small, and
other studies have reported both a decrease (Furukawa and
Mattson, 1998) and an increase in single NMDA receptor
currents (Moreno et al., 2015) in response to exogenous
APPsα delivery. More recently, we generated conditional
APP/APLP2 double KO (termed NexCre cDKO) mice that
lack APP expression and thus APPsα secretion in excitatory
forebrain neurons on a global APLP2-KO background (Hick
et al., 2015). Consistent with findings by Taylor et al. (2008),
this led to impairments in hippocampal LTP that were also
reflected in impairments in hippocampus-dependent learning
and memory tasks, including deficits in Morris water maze
and radial maze performance (Hick et al., 2015). Interestingly,
we demonstrated that acute treatment of brain slices with
nanomolar amounts of recombinant APPsα, but not APPsβ,
rescued the impairment of LTP (Hick et al., 2015). These
findings indicate a crucial ability specifically for APPsα to
support synaptic plasticity of mature hippocampal synapses
on a rapid time scale. Similar differential effects of APPsα
vs. APPsβ have been reported in assays of neuroprotection,
with APPsβ being far less effective (reviewed by Chasseigneaux
and Allinquant, 2012). Thus, the crucial functional domain
of APPsα may reside within terminal APPsα-CT16 residues,
and/or their presence alters the conformation of APPsα in a
critical way. Indeed, there is evidence from recent structural
analysis by small angle X-ray diffraction studies that the three-
dimensional structure of APPsα is very different from APPsβ
(Peters-Libeu et al., 2015). This study further suggested that
the N-terminal E1 domains folds back towards the C-terminal
juxtamembrane domain in APPsβ (Peters-Libeu et al., 2015).
Thus, epitopes that are accessible in APPsα or when provided
as peptides may become masked in APPsβ. This may have
important functional implications as distinct 3D structures may
enable or prevent binding to different receptors. Although the
receptor(s) mediating the acute effects of APPsα on synaptic
plasticity are currently unknown, they are not the endogenous
APP and APLP2 that are both lacking in NexCre cDKO mice
(Hick et al., 2015).
APPsα also appears to play an important role in processes of
natural aging. Not only is memory performance correlated with
APPsα levels (Anderson et al., 1999), but aging-related deficits in
both LTP and cognitive behavior can be rescued by exogenous
APPsα (Moreno et al., 2015; Xiong et al., 2016).
GENE EXPRESSION AND PROTEIN
SYNTHESIS
Full expression of LTP requires gene expression and de novo
protein synthesis, and this raises the question of whether
APPsα itself directly regulates protein synthesis and the
processes of translation and transcription that underlie it.
Barger and Mattson (1996a) suggested that APPsα could
regulate transcription through activation of the transcription
factor NF-kappa B (NFκB), and extensive gene expression
responses to relatively brief delivery of exogenous APPsα
have been reported (Stein et al., 2004; Ryan et al., 2013).
Gene expression responses occurred in as little as 15 min
and these slowly changed from predominantly upregulation to
predominantly downregulation during 24 h of APPsα treatment
(Ryan et al., 2013). Upregulation occurred for immediate early
gene transcription factors and for NFκB- and CREB-regulated
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genes, as well as regulation of late response genes known to be
involved in cell survival, inflammatory responses, apoptosis and
neurogenesis. These findings were further corroborated by Aydin
et al. (2011).
Although APPsα can regulate coupled transcriptional and
translational processes, it can also directly regulate protein
synthesis. Claasen et al. (2009) found, using rat hippocampal
synaptoneurosomes that are not transcriptionally competent,
that APPsα initiated de novo protein synthesis in the dendritic
compartment that was sensitive to the translation inhibitor
cycloheximide. This effect was: (1) dose-dependent with higher
concentrations failing to affect baseline protein synthesis;
(2) age-dependent with a much reduced effect in tissue from
aged rats; and (3) abolished by a PKG inhibitor and partially
blocked by inhibitors of calcium/calmodulin protein kinase II
(CaMKII), and mitogen-activated protein kinases (MAPKs).
It appears likely therefore that at least part of the LTP
facilitation by APPsα is through regulated transcriptional and
translational processes, but this hypothesis has yet to be directly
tested.
MEMORY
Intracerebral administration of antibodies against the APPsα
region of APP is able to cause learning and memory impairments
in rat inhibitory avoidance (Doyle et al., 1990; Huber et al.,
1993) as well as chick inhibitory avoidance (Mileusnic et al.,
2000) tasks. Similarly, inhibition of α-secretase impaired rat
spatial watermaze memory (Taylor et al., 2008) while APP
knock-out impaired mouse spatial learning (Ring et al., 2007).
Although these treatments are not specific manipulations of
APPsα, it is notable that memory deficits could be prevented
in a number of experiments by acute administration of either
full-length APPsα (Taylor et al., 2008) or APPsα fragments
(Mileusnic et al., 2000), or by genetic over-expression of
full-length APPsα (Ring et al., 2007). APPsα and its fragments
have also been used to rescue memory under other conditions
of impairment, such as caused by the muscarinic receptor
antagonist scopolamine (Meziane et al., 1998), Aβ (Mileusnic
et al., 2004), head injury (Corrigan et al., 2012), and aging (Xiong
et al., 2016). Moreover, viral vector mediated over-expression
of APPsα rescued memory in a mouse model of AD (Fol et al.,
2016).
There is also evidence that normal memory can be enhanced
by exogenous APPsα or peptide fragments. Full-length APPsα
enhanced go-no-go discrimination and operant lever pressing
in rats (Meziane et al., 1998) while a 17-mer fragment (derived
from the heparin binding domain located in the conserved
E2 domain) facilitated spatial memory in the watermaze
task for aged but non-memory impaired rats (Roch et al.,
1994). A 5-mer peptide internal to that fragment converted
short-term avoidance memory to long-term memory in chicks
(Mileusnic et al., 2004). These findings need to be treated
with caution, however, because transgenic over-expression
of APPsα from gestation has been shown to lead to the
development of autism-like markers such as hypoactivity
and impaired sociability (Bailey et al., 2013), as well as
aberrant T-lymphocyte development and function (Bailey et al.,
2011).
APPsα AS A THERAPEUTIC TARGET
The neurotrophic, neuroprotective, neurogenic, synaptogenic as
well as neuronal plasticity and memory enhancing properties
establish APPsα as an attractive therapeutic target during the
early stages of AD and possibly also later. In this regard
it should be kept in mind that due to the highly plastic
nature of synapses, their dysfunction and loss are reversible
processes. Thus, synaptic repair stimulated by trophic APPsα
may ameliorate pathophysiology and improve clinical outcome
as a complementary approach to eliminating toxic factors.
APPsα levels may either be enhanced by shifting APP
processing towards the non-amyloidogenic pathway or by
direct delivery/expression of exogenous APPsα (Figure 1).
Inhibiting amyloidogenic APP processing, e.g., by targeting
the Aβ-generating secretases has been a major focus of AD
research over last two decades (e.g., Yan and Vassar, 2014;
Geldenhuys and Darvesh, 2015) and several advanced BACE
inhibitors are in phase 3 clinical trials (Cumming et al.,
2012). However, using systematic proteomic approaches,
it has become clear that all secretases have numerous
substrates besides APP (Saftig and Lichtenthaler, 2015;
Kuhn et al., 2016). Pharmacological inhibition of secretases
may therefore have serious drawbacks due to mechanism-
based side effects on other targets that are important for
normal brain physiology. These concerns were further fueled
by recent findings demonstrating that BACE inhibition
upregulates non-canonical APP processing and production
of Aη fragments that impair neuronal activity and LTP (Willem
et al., 2015).
With respect to the alternative approach, enhancement
of non-amyloidogenic APP processing may be achieved by
upregulating α-secretase expression at the transcriptional level or
by modulating its subcellular trafficking or activity (for review
see Endres and Fahrenholz, 2012; Postina, 2012; Saftig and
Lichtenthaler, 2015; Habib et al., 2016).
Transcriptional Activation of ADAM10
The human ADAM10 promoter contains two retinoic acid
response elements and ADAM expression can be upregulated
at the transcriptional level by the vitamin A analog acitretin in
cells and in transgenic AD mouse models leading to increased
APPsα and reduced Aβ production (Tippmann et al., 2009). In
a small clinical trial with AD patients, acitretin, that is already
approved to treat psoriasis, was well tolerated and caused a
significant increase in APPsα levels that was detectable in CSF
samples of treated patients (Endres et al., 2014). Long-term
studies with larger patient cohorts are planned. Melatonin,
which decreases during aging and in AD patients, has been
shown to efficiently decrease Aβ levels when administered at
early stages of pathogenesis in Tg2576 AD mice (Matsubara
et al., 2003). Recently, detailed in vitro studies indicated that
the underlying mechanism involves plasma membrane-located
melatonin receptor activation, and ERK1/2 phosphorylation
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leading to increased APPsα levels via transcriptional activation of
ADAM10 and ADAM17 (Shukla et al., 2015). Moreover, and in
line with data from Moreno et al. (2015) and Xiong et al. (2016),
melatonin partially restored APPsα levels and spatial learning in
aged mice (Mukda et al., 2016).
Post-Transcriptional Activation
of α-Secretase
Although the precise mechanisms of activation are not fully
understood, it is clear that α-secretase activity, as judged by
enhanced APPsα levels, can be directly or indirectly upregulated
via ion channels, G-protein coupled receptors (GPCRs) and
receptor tyrosine kinases. In particular, receptor-activated
protein kinase C, MAP kinases, PI3 kinase and Ca2+ signaling
have been shown to contribute to α-secretase activation. In
many cases, however, it has not been directly studied which
enzymes mediate increased APPsα production. In these cases
processing may involve ADAM10 and/or ADAM17 and possibly
further metalloproteases that have been shown to have APP
cleaving activity in vitro (Saftig and Lichtenthaler, 2015). As a
detailed description of these various pharmacological approaches
is beyond the scope of this review, the reader is referred to a series
of recent reviews (see Postina, 2012; Saftig and Lichtenthaler,
2015; Habib et al., 2016; Spilman et al., 2016).
Upregulation of α-secretase activity was reported for
etazolate, an allosteric activator of GABAA receptors, which
increased APPsα in rat cortical neurons and guinea pig brain
(Marcade et al., 2008), improved memory in aged rats (Drott
et al., 2010) and proved protective against traumatic brain
injury (Siopi et al., 2013). The neuropeptide pituitary adenylate
cyclase-activating polypeptide (PACAP) potently increased
APPsα levels, an effect that was abrogated by an antagonist of
the GPCR PAC1, by a hydroxamate-based ADAM inhibitor
and by inhibitors of MAP kinases and PI3 kinases (Kojro et al.,
2006). In vivo, APPsα production in the brain was stimulated
by long-term intranasal PACAP application. The effects of
PACAP application were not limited to increased APPsα levels
but were instead pleiotropic, including upregulation of the
PAC1 receptor, BDNF and of the anti-apoptotic Bcl-2 protein
(Rat et al., 2011). While these in vivo effects, including improved
object recognition in transgenic AD model mice (Rat et al.,
2011), appear favorable for treatment, Gardoni et al reported
that PACAP treatment of primary hippocampal neurons led
to postsynaptic ADAM10 accumulation and N-cadherin-
dependent reductions in spine head volume and reduced
postsynaptic GluR1 expression (Gardoni et al., 2012). Thus a
more detailed in vivo characterization appears warranted.
Activation of serotonin type 4 receptors (5-HT4Rs), another
class of neuronally expressed GPCR, promotes the activity
of ADAM10 and APPsα generation. The 5-HT4R was shown
to directly interact with the mature form of ADAM10 and
agonist stimulation of the receptor accelerated ADAM10 activity
by cAMP/Epac (cAMP-responsive Rap1 guanine nucleotide
exchange factor) signaling (Cochet et al., 2013). Tesseur et al.
(2013) reported that chronic 5-HT4 receptor activation lowered
Aβ production in transgenic hAPP/PS1 AD model mice but the
authors found no evidence for a direct activation of ADAM10.
The underlying mechanism appears more complex and may
involve decreased APP and BACE-1 expression and elevated
astroglial and microglial responses. More recently, donecopride,
a promising synthetic multitargeted ligand that functions both
as a partial agonist of 5-HT4R and as an acetylcholinesterase
inhibitor, has been developed and shown to have memory
enhancing ability (Lecoutey et al., 2014).
Direct Expression of APPsα in the CNS
Although α-secretase-targeting pharmacological strategies are
potentially promising, there remains the concern regarding lack
of specificity (see for example Gardoni et al., 2012). Acitretin
may induce other genes with retinoid response elements in their
promoters and upregulation of α-secretase activity (ADAM10,
17 or others) will likely lead to the processing of many
additional substrates. In this regard, Kuhn et al. (2016) recently
demonstrated that ADAM10 has over 40 neuronal substrates
including some involved in tumorigenesis. Thus, it is still unclear
whether increasing α-secretase activity in neural tissue will
ultimately be of therapeutic benefit for patients. An approach to
circumvent these problems is the direct delivery of APPsα into
the brain.
While previous studies demonstrated the neuroprotective
properties of APPsα against acute forms of brain injury (VanDen
Heuvel et al., 1999; Thornton et al., 2006; Corrigan et al., 2012,
2014; Plummer et al., 2016) the situation is quite different in
neurodegenerative diseases such as AD, characterized by chronic
production and accumulation of neurotoxic molecules including
Aβ. Another challenge is the need for sustained expression
of neurotrophic/neuroprotective factors. This calls for a gene
therapy approach. During recent years gene therapy approaches
to neurological disorders including AD have been explored
in preclinal studies and also entered phase I/II clinical trials
(Tuszynski et al., 2015; Choudhury et al., 2016b; Fol et al.,
2016; Hocquemiller et al., 2016). For the CNS, adeno-associated
virus (AAV) vector systems have been most commonly used due
to their safety, non-pathogenic nature, the ability to transduce
dividing and non-dividing cells, particularly neurons in vivo, the
wide volumetric distribution of vector particles in tissue and the
ability to mediate long-term gene expression in vivo (Choudhury
et al., 2016a; Hocquemiller et al., 2016).
Recently, we employed AAV9-mediated gene transfer of
APPsα into the brain to explore its potential to ameliorate or
rescue structural, electrophysiological and behavioral deficits
of transgenic APP/PS1 AD model mice. A single bilateral
injection of AAV-APPsα particles was sufficient to mediate
long-lasting APPsα expression over 5 months that was well
tolerated without apparent side effects. Interestingly, sustained
APPsα overexpression in aged APP/PS1 mice with already
preexisting pathology and amyloidosis restored LTP, ameliorated
spine density deficits and also rescued spatial reference memory
assessed by the Morris water maze. Moreover, we demonstrated
a significant reduction of soluble Aβ species and plaque load.
In addition, APPsα treatment induced the recruitment of
microglia with a ramified morphology into the vicinity of
plaques and upregulated IDE and TREM2 expression suggesting
enhanced plaque clearance (Fol et al., 2016). These data
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further corroborate the therapeutic potential of APPsα for
AD that raises hope to translate these findings into clinical
application.
To this end further experimental studies including different
routes of viral vector application, dose optimization and
studies in lager animals are needed. Several routes of vector
administration to the CNS have been developed: (i) direct
injection into the brain parenchyma; (ii) CSF-based delivery
using ICV, cisternal or lumbar intrathecal (IT) administration;
and (iii) intravascular (e.g., intravenous) administration.
Intracranial injection has been explored not only for diseases
with anatomically restricted pathology such as Parkinson’s
disease (reviewed in Choudhury et al., 2016b; Hocquemiller
et al., 2016), but also for neuropathic lysosomal storage
diseases (LSD) that affect large brain regions. For LSDs,
multiple intraparenchymal injections were used in phase I/II
clinical trials that showed the safety of the approach and
also lead to encouraging clinical outcome (Leone et al., 2012;
Tardieu et al., 2014). Vector delivery via the CSF’, in particular
intracisternal and IT is a less invasive alternative strategy that
is particularly promising for the delivery of secreted proteins
such as growth factors and lysosomal proteins, and has been
successfully used to express Apolipoprotein E in AD model
mice (Hudry et al., 2013). Systemic, intravascular administration
is the least invasive route and has the potential to enable
wide spread vector distribution as every cell in the brain
being a maximum of 40 microns from the microvasculature
(Wong et al., 2013). In this regard encouraging progress
has been made, as serotype AAV9 and AAVrh.10 have been
shown to cross to some extent the blood brain barrier (BBB;
reviewed in Hocquemiller et al., 2016; Saraiva et al., 2016),
apparently by active transcytosis through endothelial cells
(Merkel et al., 2017). The development of modified AAV
vectors with re-engineered capsids should improve this further
(Choudhury et al., 2016a; Deverman et al., 2016; Jackson
et al., 2016). One of the main challenges for AD gene therapy
is the widespread pathology that affects several anatomic
regions involved in learning and memory. Thus, protocols
that either target regions affected early during disease and/or
widespread gene delivery to several anatomical regions are
required.
A non-invasive alternative to viral vector mediated gene
transfer are formulations of recombinant APPsα protein,
sub-domains or active peptides that enable transport across the
BBB. This includes intranasal delivery that has been successfully
used in preclinical models of CNS diseases (Lochhead and
Thorne, 2012). Examples for AD are the intranasal delivery of
insulin (Mao et al., 2016) or PACAP (Rat et al., 2011) to enhance
non-amyloidogenic APP processing in transgenic mouse models.
Liposomes and nano-particle based approaches are emerging
as further options (Kreuter, 2014; Khalin et al., 2016). Finally,
transient opening of the BBB by transcranial focused or scanning
ultrasound in combination with microbubbles might be used to
further enhance delivery of viral vectors, proteins such as APPsα
(or active fragments) and nano-particles (Thévenot et al., 2012;
Leinenga et al., 2016).
Collectively, these various approaches all appear to merit
further investigation. However it needs to be kept in mind that
many challenges lie ahead for translating these approaches to the
human brain, especially given its size and thus the widespread
volume of brain tissue that needs to be treated. Moreover, the
preclinical animal models being currently used do not fully
recapitulate the human disease features, and thus successes in
animal models need to be treated with caution. Nonetheless,
despite these challenges the neuroprotective and synaptic repair
inducing properties of APPsα make it a worthy target for future
research aiming to treat AD, as well holding other neurological
disorders.
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